Structure-based drug design of a new chemical class of small molecules active against influenza A nucleoprotein in vitro and in vivo.

PLoS Curr

Chief Scientific Officer, Quantum Pharmaceuticals; Pharmacology, Biotechnology, Molecular biology, Molecular oncology; Researcher, Quantum Pharmaceuticals Moscow; Quantum Pharmaceuticals, Researcher, Software Developer and CEO, Quantum Pharmaceticals Moscow.

Published: August 2011

We report preliminary results and a summary of a bottom-up approach to identify new, active, nontoxic, small-molecule antivirals designed to have а novel mechanism of action. We employed the procedure to identify 3-mercapto-1,2,4-triazoles derivatives as potential NP inhibitors in silico and subsequently demonstrated the in vitro efficacy of the molecules against various strains of the influenza A virus. The most efficacious compounds were successfully tested in an in vivo influenza challenge experiment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3153361PMC
http://dx.doi.org/10.1371/currents.RRN1253DOI Listing

Publication Analysis

Top Keywords

structure-based drug
4
drug design
4
design chemical
4
chemical class
4
class small
4
small molecules
4
molecules active
4
active influenza
4
influenza nucleoprotein
4
nucleoprotein vitro
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!